Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.47 |
| ▸ | LPL | P06858 | 4/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 5/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20392825 | 0.89 | SNCA (0.50) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL16267992 | 0.83 | SNCA (0.50) | SNCALPLLIPGALPLHPGDS | |
| SCHEMBL14842080 | 0.81 | CYP1A2 (0.45) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL2508208 | 0.81 | SNCA (0.54) | SNCALPLLIPGIRAK4CA1 | |
| SCHEMBL30276774 | 0.81 | SNCA (0.54) | SNCALPLLIPGIRAK4CA1 | |
| SCHEMBL26623552 | 0.80 | LPL (0.38) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL30628945 | 0.80 | LPL (0.38) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL14721612 | 0.80 | EGFR (0.43) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL6033638 | 0.80 | LPL (0.47) | SNCALPLLIPGALPLIRAK4 | |
| SCHEMBL7601195 | 0.79 | LIPG (0.58) | SNCALPLLIPGIRAK4PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | SNCA 4042/4885LPL 299/4885LIPG 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.